No Picture
News

ImmunoScape Targets Immunology Breakthroughs for COVID-19 and Oncology with $11M in Global Financing Led by Anzu Partners and UTEC

The funds enable ImmunoScape to bring its unique immune-profiling capability to major biopharma companies globally, accelerating development of vital immunotherapies and other medicines

SINGAPORE and SAN DIEGO, Aug. 12, 2020 /PRNewswire/ — ImmunoSc… […]

No Picture
News

Qualigen Therapeutics, Inc. Announces $10 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

CARLSBAD, Calif., Aug. 2, 2020 /PRNewswire/ — Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or the “Company”), today announced it has entered into a definitive agreement with a single institutional investor for the purchase and sale for $1… […]

No Picture
News

Viking Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Conference call scheduled for 4:30 p.m. ET today- Enrollment Continues in Phase 2b VOYAGE Study of VK2809 in NASH; New Data from 12-Week Phase 2 Trial to be Highlighted at EASL- IND Filed for VK0214 in X-ALD; Phase 1 Trial Expected to Begin Q3 2020- Ba… […]

No Picture
News

HemaFlo Therapeutics, Inc. Engages VENTURE.co Brokerage Services for $7.5 MM Private Placement Offering

Company Focused on Finding an Effective Solution for Acute Kidney Injury (AKI)

CARLSBAD, Calif., May 28, 2020 /PRNewswire/ — Venture.co Brokerage Services, LLC (“VENTURE.co”) today announces a private capital investment opportunity into HemaFlo Ther… […]

No Picture
News

Cardiff Oncology Enters Agreement with PoC Capital to Fund Phase 2 Clinical Trial of Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer (mCRC)

– Funding will also enable the addition of new trial sites to accelerate completion of the Phase 2 clinical trial- Data continues to demonstrate the safety and efficacy of onvansertib as a promising new treatment for patients with KRAS-mutated mCRC

S… […]

No Picture
News

Sweetwater Private Equity recognizes Adaptive Biotechnologies Corp. and its CEO Chad Robins for leadership during COVID-19 crisis

SAN DIEGO, April 28, 2020 /PRNewswire/ –?Sweetwater Investment Management (“Sweetwater” or “Sweetwater Private Equity” (dba)) announced during their recent annual investor meeting the selection of Chad Robins, CEO of Adaptive Biotechnologies Corp. … […]

No Picture
News

Aspen Neuroscience Announces $70 Million Series A Financing Led by OrbiMed to Advance Development of the First Autologous Neuron Replacement Therapy to Treat Parkinson Disease

SAN DIEGO, April 1, 2020 /PRNewswire/ — Aspen Neuroscience, a private biotechnology company developing the first autologous neuron replacement therapy to treat Parkinson disease, today announced the close of its Series A funding round of $70 millio… […]